- Home
- ITOS vs LEO Comparison
ITOS vs LEO Comparison
Compare ITOS & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- LEO
- Stock Information
- Founded
- ITOS 2011
- LEO 1987
- Country
- ITOS United States
- LEO United States
- Employees
- ITOS N/A
- LEO N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- LEO Trusts Except Educational Religious and Charitable
- Sector
- ITOS Health Care
- LEO Finance
- Exchange
- ITOS Nasdaq
- LEO Nasdaq
- Market Cap
- ITOS 381.2M
- LEO 362.5M
- IPO Year
- ITOS 2020
- LEO N/A
- Fundamental
- Price
- ITOS $10.17
- LEO $5.78
- Analyst Decision
- ITOS Hold
- LEO
- Analyst Count
- ITOS 6
- LEO 0
- Target Price
- ITOS $10.60
- LEO N/A
- AVG Volume (30 Days)
- ITOS 1.5M
- LEO 200.2K
- Earning Date
- ITOS 08-07-2025
- LEO 01-01-0001
- Dividend Yield
- ITOS N/A
- LEO 4.01%
- EPS Growth
- ITOS N/A
- LEO N/A
- EPS
- ITOS N/A
- LEO 0.04
- Revenue
- ITOS $35,000,000.00
- LEO N/A
- Revenue This Year
- ITOS N/A
- LEO N/A
- Revenue Next Year
- ITOS N/A
- LEO N/A
- P/E Ratio
- ITOS N/A
- LEO $152.00
- Revenue Growth
- ITOS 177.89
- LEO N/A
- 52 Week Low
- ITOS $4.80
- LEO $4.98
- 52 Week High
- ITOS $18.13
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- ITOS 58.43
- LEO 44.18
- Support Level
- ITOS $10.10
- LEO $5.71
- Resistance Level
- ITOS $10.47
- LEO $5.81
- Average True Range (ATR)
- ITOS 0.12
- LEO 0.06
- MACD
- ITOS -0.06
- LEO -0.01
- Stochastic Oscillator
- ITOS 23.08
- LEO 25.93
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.